(Q40181537)

18 September 2017

title

mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft (English)

1 reference

18 September 2017

1 reference

1 reference

1 reference

Satoshi Inoue

1

1 reference

18 September 2017

Amanda Hartman

2

1 reference

18 September 2017

Cynthia D Branch

3

1 reference

18 September 2017

Corazan D Bucana

4

1 reference

18 September 2017

Benjamin N Bekele

5

1 reference

18 September 2017

L Clifton Stephens

6

1 reference

18 September 2017

Sunil Chada

7

1 reference

18 September 2017

Rajagopal Ramesh

8

1 reference

18 September 2017

publication date

1 February 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

15

1 reference

18 September 2017

issue

2

1 reference

18 September 2017

page(s)

287-294

1 reference

Tumor angiogenesis: therapeutic implications

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Gene therapeutic exploration: retrovirus-mediated soluble vascular endothelial growth factor receptor-2 (sFLK-1) inhibits the tumorigenicity of S180, MCF-7, and B16 cells in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Antiangiogenesis and Damaging Blood Flow by Antisense Vascular Endothelial Growth Factor Oligodeoxynucleotides to Suppress Lung Cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300035

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300035

1 reference

18 September 2017

1 reference